Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease
source: New England Journal of Medicine
year: 2021
authors: Julie Kanter, Mark C. Walters, Lakshmanan Krishnamurti, Markus Y. Mapara, Janet L. Kwiatkowski, Stacey Rifkin-Zenenberg, Banu Aygun, Kimberly A. Kasow, Francis J. Pierciey, Jr., Melissa Bonner, Alex Miller, Xinyan Zhang, Jessie Lynch, Dennis Kim, Jean-Antoine Ribeil, Mohammed Asmal, Sunita Goyal, Alexis A. Thompson, John F. Tisdale
summary/abstract:Background: Sickle cell disease is characterized by the painful recurrence of vaso-occlusive events. Gene therapy with the use of LentiGlobin for sickle cell disease (bb1111; lovotibeglogene autotemcel) consists of autologous transplantation of hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified β-globin gene, which produces an antisickling hemoglobin, HbAT87Q.
Methods: In this ongoing phase 1-2 study, we optimized the treatment process in the initial 7 patients in Group A and 2 patients in Group B with sickle cell disease. Group C was established for the pivotal evaluation of LentiGlobin for sickle cell disease, and we adopted a more stringent inclusion criterion that required a minimum of four severe vaso-occlusive events in the 24 months before enrollment. In this unprespecified interim analysis, we evaluated the safety and efficacy of LentiGlobin in 35 patients enrolled in Group C. Included in this analysis was the number of severe vaso-occlusive events after LentiGlobin infusion among patients with at least four vaso-occlusive events in the 24 months before enrollment and with at least 6 months of follow-up.
Results: As of February 2021, cell collection had been initiated in 43 patients in Group C; 35 received a LentiGlobin infusion, with a median follow-up of 17.3 months (range, 3.7 to 37.6). Engraftment occurred in all 35 patients. The median total hemoglobin level increased from 8.5 g per deciliter at baseline to 11 g or more per deciliter from 6 months through 36 months after infusion. HbAT87Q contributed at least 40% of total hemoglobin and was distributed across a mean (±SD) of 85±8% of red cells. Hemolysis markers were reduced. Among the 25 patients who could be evaluated, all had resolution of severe vaso-occlusive events, as compared with a median of 3.5 events per year (range, 2.0 to 13.5) in the 24 months before enrollment. Three patients had a nonserious adverse event related or possibly related to LentiGlobin that resolved within 1 week after onset. No cases of hematologic cancer were observed during up to 37.6 months of follow-up.
Conclusions: One-time treatment with LentiGlobin resulted in sustained production of HbAT87Q in most red cells, leading to reduced hemolysis and complete resolution of severe vaso-occlusive events. (Funded by Bluebird Bio; HGB-206 ClinicalTrials.gov number, NCT02140554.).
organization: University of Alabama Birmingham, USA; UCSF Benioff Children's Hospital, USA; Children's Healthcare of Atlanta, USA; Columbia University Medical Center, USA; Cohen Children's Medical Center, USA; Zucker School of Medicine at Hofstra-Northwell, USA; Children's Hospital of Philadelphia, USA; University of Pennsylvania Perelman School of Medicine, USA; Hackensack University Medical Center, USA; University of North Carolina at Chapel Hill, USA; Bluebird Bio, USA; Northwestern University Feinberg School of Medicine, USA; Ann and Robert H. Lurie Children's Hospital, USA; National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases, USA; National Institutes of Health, USADOI: 10.1056/NEJMoa2117175
read more full text
+myBinderRelated Content
-
Clinical trial offers hope to adults with sickle cell diseaseAt 33, Alexis Jones-Heggs has known a li...
-
Chief Patient Officer SummitJuly 18-20 | Boston, Massachusetts This...
-
New Pre-transplant Treatment Regimen Improves Survival of Kids with Sickle Cell Disease, Trial ShowsA new pre-transplant conditioning regime...
-
Alzheimer’s Treatment Memantine Shows Promise in Treating Sickle Cell DiseaseMemantine, a standard treatment for Alzh...
-
Folate supplementation in people with sickle cell diseaseBACKGROUND: Sickle cell disease is a gr...
-
Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell...Discovery and validation of genetic vari...
-
Successful Gene Therapy for Sickle Cell DiseasePrior to this report, the only curative ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.